PDCD1 and colorectal carcinoma: In this study, we examined whether poly(I:C) and LAG-3-Ig immune adjuvants with neoantigen peptides (hereafter referred to as Comb) can surmount the limited anti-tumour efficacy associated with reduced doses of anti-PD-1 monoclonal antibody (RD-αPD-1 mAb) in mouse CRC tumour models.